Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States
Top Cited Papers
Open Access
- 21 May 2022
- journal article
- research article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (9) , 581.e1-581.e8
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute (U24 CA233032)
- Janssen Pharmaceutica
- Amgen
- Cidara Therapeutics
- Bristol-Myers Squibb
- TG Therapeutics
- Pfizer
- Kite Pharma
- AbbVie
- Merck
- Seagen
- Novartis
- Miltenyi Biotec
- Gilead Sciences
- Servier
- Celgene
- Kyowa Kirin Pharmaceutical Development
- AstraZeneca
- Tessa Therapeutics
- Astellas Pharma US
This publication has 18 references indexed in Scilit:
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trialThe Lancet Oncology, 2019
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaNew England Journal of Medicine, 2017
- Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 studyBlood, 2017
- Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneityBlood, 2015
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano ClassificationJournal of Clinical Oncology, 2014
- Current concepts in the diagnosis and management of cytokine release syndromeBlood, 2014
- Management of relapsed-refractory diffuse large B cell lymphomaSouth Asian Journal of Cancer, 2014
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCTBlood, 2005
- Partial residuals for the proportional hazards regression modelBiometrika, 1982